Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Revamped Web site for electrophoresis products, 7/13:108

Hoefer’s new Web site was designed to create a more positive experience with improved navigation, more product information, an enhanced storefront, and more technical literature available to download. A dealer portal section has also been added to improve the communication of support materials with channel partners. The site was designed to resize to device-display resolution, enabling a better experience for desktops, tablets, and mobile devices.

Anti-herpes, HCV panels, 7/13:107

SeraCare Life Sciences offers three new Accuvert seroconversion panels and one new Accuset performance panel. The new Accuvert seroconversion panels are HCV seroconversion panel PHV924, providing undiluted plasma samples from a single male donor of genotype 2b, drawn over an 88-day period in 2008; HCV seroconversion panel PHV925, providing undiluted plasma samples from a single male donor of genotype 1a, drawn over a 27-day period in 2008; and HCV seroconversion panel PHV926, providing undiluted plasma samples from a single male donor of genotype 3a, drawn over a 14-day period in 2009.

High-volume optical filter manufacturing facility, 7/13:106

Last year, Semrock opened a high-capacity manufacturing facility for its optical filter products. Having entered full-scale production, the company now supports its OEM customers by producing spectrally complex, hard-coated sputtered optical filters with high-volume pricing. Semrock’s products are available to the emerging diagnostic and point-of-care health care and display and sensing markets, where high-performance, miniaturized optical filters are an enabling technology.

Qiagen deals for cancer biomarkers, 7/13:107

Qiagen announced two agreements that add biomarkers involving glioblastoma, lymphoma, and other cancers to the company’s portfolio of potential companion diagnostics. In the glioblastoma project, Qiagen has entered into an exclusive worldwide licensing option with Columbia University in New York on FGFR-TACC fusion genes. Qiagen intends to develop this biomarker into a test for routine use in diagnostic workups, which may allow doctors to identify glioblastoma patients who could benefit from targeted treatments.

Cardiovascular genetic testing, 7/13

Aviir Inc. is increasing its offered services with a comprehensive inherited cardiovascular disease genetic test menu. The newly validated tests cover the major causes of cardiomyopathies, arrhythmia disorders, and other genetically transmitted diseases that affect the heart and vasculature. Each test is available for individual and familial settings. Two comprehensive panels are available to check for undiagnosed arrhythmia or cardiomyopathy.

Biosearch acquires VitraBio, DNA Technology, 7/13:106

Biosearch Technologies has acquired the oligonucleotide manufacturing division of Danish company DNA Technology and the German CPG manufacturer VitraBio. With the acquisition of DNA Technology, Biosearch adds a skilled production team with a mature quality system and an established European customer base focused in the Nordic countries.

Automated system for nucleic acid extraction, 7/13:106

Hamilton Robotics has collaborated with Macherey-Nagel to create the Genomic Starlet automated liquid handling workstation. The system extracts nucleic acids from biological samples and purifies PCR products in a non-IVD environment.

CLIA waiver studies for HIV 1/2 assay, 7/13:106

Chembio Diagnostics has commenced CLIA waiver studies for its DPP HIV 1/2 assay. In December 2012, Chembio received FDA approval for its DPP HIV 1/2 assay, which detects antibodies to HIV 1/2 in oral fluid, fingerstick whole blood, venous whole blood, serum, or plasma samples.

Beckman Coulter, Illumina automate NGS applications, 7/13:106

Through a partnership with Illumina, Beckman Coulter Life Sciences will develop, distribute, and support automation for Illumina’s TruSeq and Nextera next-gen sequencing sample preparation kits. Illumina will provide technical expertise on chemistry and protocols.

Enhanced capability for molecular diagnostic system

Abbott has introduced a new capability for its RealTime m2000 system to enhance the system’s flexibility and make molecular testing easier and more efficient. Abbott’s mPlus makes it possible for laboratories to perform molecular diagnostic tests for infectious disease detection and therapy monitoring.

MARKETPLACE

TRENDING